Olivier Brandicourt

We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which Olivier Brandicourt is associated, including Medivation and board. Most recently, Olivier Brandicourt has been quoted saying: “In 2017 and beyond we will continue to simplify and reshape the company. We will be supported by our current growth engine businesses: Sanofi Genzyme, vaccines and consumer healthcare. The only principle we will follow is to create value for shareholders and always consider the strategic fit.” in the article Drugmaker Sanofi sees weak 2017 earnings, not in hurry for M&A.

Olivier Brandicourt quotes

Automatically powered by

In 2017 and beyond we will continue to simplify and reshape the company. We will be supported by our current growth engine businesses: Sanofi Genzyme, vaccines and consumer healthcare. The only principle we will follow is to create value for shareholders and always consider the strategic fit.

We can grow without M&A. However, it is a tool which we do continue to consider and which can help growth potentially, only if it makes sense strategically. The reason why it is so competitive is that you don't have a very, very large number of potential targets.

Shareholders being frustrated after one year is not automatically what I'm hearing, to be honest, because when I see investors they seem to be very happy for us not to have spent $14 billion on Medivation. On Actelion, I'm not making any comment but you will understand that a company like ours will continuously look at what's happening in the world of potential mergers and acquisitions.

We are making significant concessions but patients are paying more.

We are opening our M&A strategy, as we said last year, to segments where have a good presence but where we need to strengthen our presence with inorganic growth, we mentioned immunology and we mentioned MS... rare disease can also be an area.

We're certainly pleased to have the opportunity to engage with Medivation. But I emphasize that we will remain financially disciplined throughout this process.

We believe we have offered a fair price, and a very attractive premium. We remain enthusiastic about a potential combination with Medivation.

If the Medivation board of directors continues to refuse to engage with us, then we intend to commence a process to remove and replace members of the board.

We also strongly believe that Medivation shareholders would find our proposal to be compelling.

No quotes...
More Olivier Brandicourt quotes
|< <
{{currentQuotePage}}/{{numberPage}}
> >|
<
>